BJDX
Bluejay Diagnostics, Inc. NASDAQ Listed Nov 10, 2021$0.83
-1.88%
vs $0.85
Mkt Cap $859.0K
52w Low $0.80
0.2% of range
52w High $16.68
50d MA $0.95
200d MA $2.08
P/E (TTM)
—
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.0x
ROE
-114.6%
P/FCF
-0.1x
RSI (14)
45.10
ATR (14)
$0.06
Beta
0.67
50d MA
$0.95
200d MA
$2.08
Avg Volume
2.3M
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
360 Massachusetts Avenue · Acton, MA 01720 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | AMC | -3520.00 | -1.12 | +100.0% | 1.05 | -4.8% | +1.0% | -0.9% | -2.9% | -4.9% | -1.0% | — |
| May 13, 2026 | AMC | — | -1.95 | — | 1.78 | -0.6% | -1.7% | -4.6% | +3.0% | -0.6% | +4.1% | — |
| Mar 6, 2026 | AMC | — | -2.37 | — | 1.86 | -0.5% | +0.5% | +2.7% | +5.7% | -2.5% | -4.0% | — |
| Nov 7, 2025 | AMC | — | -4.04 | — | 6.28 | -0.6% | +0.0% | +10.2% | -6.4% | -4.3% | -4.5% | — |
| Aug 7, 2025 | AMC | -144.00 | -5.64 | +96.1% | 5.88 | -0.7% | -4.8% | +34.3% | -21.3% | -6.8% | -5.1% | — |
| May 13, 2025 | AMC | -1152.00 | -13.48 | +98.8% | 7.24 | -3.9% | -5.5% | +4.1% | +0.6% | +7.8% | -1.0% | — |
| Mar 31, 2025 | AMC | -832.00 | -449.48 | +46.0% | 14.92 | -0.3% | -2.9% | +2.2% | -12.2% | +8.6% | +112.5% | — |
| Nov 7, 2024 | AMC | -1304.00 | -32.00 | +97.5% | 18.52 | -13.6% | -1.7% | +3.5% | +14.6% | -3.7% | -28.8% | — |
| Aug 14, 2024 | AMC | -144.00 | -1024.00 | -611.1% | 59.56 | -1.9% | +2.8% | -12.4% | +12.2% | -4.9% | -10.8% | — |
| May 15, 2024 | AMC | -1152.00 | -396.00 | +65.6% | 840.00 | +6.4% | +9.5% | +0.9% | -6.8% | -5.6% | -3.0% | — |
| May 8, 2024 | AMC | -1920.00 | -3840.00 | -100.0% | 832.00 | +3.3% | -1.9% | -1.5% | +4.5% | +4.9% | -4.5% | — |
| Mar 28, 2024 | AMC | -0.68 | -2848.00 | -9999.0% | 1284.48 | -1.3% | -4.0% | -1.9% | -4.8% | -1.7% | -6.7% | — |
| Nov 9, 2023 | AMC | -0.82 | -3328.00 | -9999.0% | 5040.00 | +0.8% | +5.7% | +1.8% | -2.7% | +3.0% | -2.1% | — |
| Aug 14, 2023 | AMC | -600.00 | -1100.00 | -83.3% | 12368.00 | +12.4% | -2.2% | +0.9% | -1.2% | -3.6% | +2.8% | — |
| May 10, 2023 | AMC | -480.00 | -960.00 | -100.0% | 9283.20 | +6.9% | +3.4% | -6.7% | +0.0% | -1.5% | +15.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3 | Dawson James | Downgrade | Buy → Neutral | — | $8736.00 | $16800.00 | +92.3% | +52.2% | -4.2% | +2.9% | +7.7% | -5.9% |
| Jan 12 | Dawson James | Maintains | Buy → Buy | — | $87680.00 | $101440.00 | +15.7% | +0.0% | -2.9% | +0.0% | -3.2% | -4.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | HRT FINANCIAL LP10% | — | Sell | 34,938 | $1.40 | $49K | 92,055 | +2.46% | -16.55% |
| Jul 9, 2026 | HRT FINANCIAL LP10% | — | Buy | 64,047 | $1.51 | $97K | 126,993 | +2.46% | -16.55% |
| Mar 14, 2026 | CHASE DONALD RDir | — | Buy | 12,500 | $2.00 | $25K | 12,525 | -0.58% | +0.52% |
| Mar 14, 2026 | ZEIDMAN FRED SDir | — | Buy | 12,500 | $2.00 | $25K | 12,500 | -0.58% | +0.52% |
| Mar 14, 2026 | Dey SvetlanaDir | — | Buy | 12,500 | $2.00 | $25K | 12,501 | -0.58% | +0.52% |
| Mar 14, 2026 | Dey IndranilDir/Off | President and CEO | Buy | 12,500 | $2.00 | $25K | 12,522 | -0.58% | +0.52% |
| Mar 14, 2026 | Wurth Douglas ClarkDir | — | Buy | 12,500 | $2.00 | $25K | 12,608 | -0.58% | +0.52% |
8-K · 7.01
! Medium
Bluejay Diagnostics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 13
8-K · 5.02
!!! Very High
Bluejay Diagnostics, Inc. -- 8-K 5.02: Executive Change
Jun 9
8-K · 3.02
!! High
Bluejay Diagnostics, Inc. -- 8-K 3.02: Unregistered Securities Offering
Jun 8
8-K · 1.01
!! High
Bluejay Diagnostics, Inc. -- 8-K 1.01: Material Agreement
Jun 2
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Bluejay Diagnostics completed enrollment of 624 patients in its SYMON-II pivotal trial, moving the diagnostic company closer to potential FDA approval and commercialization, which could validate its technology and drive future revenue.
Apr 7
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
BJDX entered into a material agreement that could significantly impact business operations or financial performance, requiring immediate investor attention to the full filing details for revenue, cost, or strategic implications.
Mar 17
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Bluejay Diagnostics disclosed a March 13 letter to major investor Northstrive Fund II, suggesting potential negotiations or disputes that could materially affect capital structure or operations—investors should monitor for dilution or strategic changes.
Mar 16
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Bluejay's sepsis treatment data presentation at SAEM conference validates clinical progress, potentially supporting future regulatory approval and commercialization timelines for investors monitoring pipeline advancement.
Mar 12
8-K
Bluejay Diagnostics, Inc. -- 8-K Filing
Bluejay Diagnostics (BJDX) outlined its 2026 strategic priorities and corporate progress as a medical diagnostics company focused on rapid critical care testing solutions.
Mar 6
8-K · 7.01
! Medium
Bluejay Diagnostics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Bluejay Diagnostics disclosed warrant and capitalization updates via press release, though the specific details require reviewing the full exhibit to assess potential shareholder impact.
Feb 20
8-K · 7.01
! Medium
Bluejay Diagnostics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Bluejay Diagnostics announced progress on clinical study enrollment and manufacturing readiness, potentially signaling advancement toward commercialization of its diagnostic products.
Feb 18
Institutional (13F) — Top 3
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ubs Group Ag | 124 | $228 | New | Mar 2026 |
| 2 | L1 Global Manager Pty Ltd | 120 | $144 | New | Jun 2026 |
| 3 | Caitong International Asset Management Co., Ltd | 1 | $1 | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 8,887 | $18K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 183 | $392 | May 2026 |
Valuation
Market Cap
$859K
Enterprise Value
-$4.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
0.06x
P/S
—
P/FCF
-0.06x
EV/EBITDA
—
Shares Out
449K
Financials (TTM)
Revenue
$0
Net Income
-$7.3M
EBITDA
-$7.1M
Free Cash Flow
-$6.2M
Op Cash Flow
-$6.1M
EPS Basic
$-15.25
EPS Diluted
$-11.80
EPS Forward
$-464.00
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$7.1M
Total Liab.
$1.1M
Total Equity
$6.0M
Cash
$5.2M
LT Debt
$20K
Book Value/Sh
$13.31
Debt/Equity
0.02x
Current Ratio
4.88
Quick Ratio
4.88
Returns & Growth
ROE
-114.6%
ROA
-96.2%
ROIC
-114.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+96.7%
Price Returns
2W
+0.1%
1M
-0.4%
3M
-25.8%
6M
-56.6%
12M
-86.9%
Technicals
52W High
$16.68
52W Low
$0.80
50d MA
$0.95
200d MA
$2.08
RSI (14)
45.10
ATR (14)
$0.06
Beta
0.67
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 9:46pm
· Source: financialmodelingprep.com